Prevalence of Pregnancy in Polycystic Ovary Syndrome

NCT03157921 | Completed

• 1 other identifier: 17100186
• Study Type: observational
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, with a prevalence of approximately 5-10%. Polycystic ovary syndrome is diagnosed according to Rotterdam criteria by at least two of the following three key features: oligomenorrhea or amenorrhea; clinical and/or biochemical signs of hyperandrogenism; the presence of polycystic ovaries on ultrasound and exclusion of other endocrine disorders including hyperprolactinemia, thyroid dysfunction and congenital adrenal hyperplasia. Polycystic ovary syndrome is also associated with insulin resistance, obesity and disorders of lipid metabolism, as well as infertility, although these findings have not been addressed in the Rotterdam criteria. Polycystic ovary syndrome is the major cause of anovulatory infertility. The recent studies suggest that anovulation resulting from ovarian follicle abnormalities in Polycystic ovary syndrome patients are 2-fold of normal ovaries. Firstly, early follicular growth is excessive, thus women with Polycystic ovary syndrome are characterized by an excessive number of small antral follicles (2- to 3-fold of normal ovaries). Secondly, the selection of one follicle from the increased pool of selectable follicles and its further maturation to a dominant follicle does not occur. This second abnormality in the folliculogenesis can cause menstrual dysfunction presented as oligomenorrhea or amenorrhea. Historically, Polycystic ovary syndrome treatment has not been curative in nature, instead treatments focus on resolution of clinical manifestations of the disease.

Conditions

Polycystic Ovary Syndrome

Outcome Measures

Primary Outcomes (1)

• Number of poly-cystic ovarian syndrome women who will be ovulated

  3 months

Interventions

transvaginal ultrasound RADIATION

assessment of ovarian volume and antral follicle count

Hormonal levels DIAGNOSTIC_TEST

follicle stimulating hormone level, luteinizing hormone level and anti-mullerian hormone level

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: female
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

infertile women with poly-cystic ovary syndrome

You may qualify if:

• infertile women
• age from 18 to 40 years
• poly-cystic ovary syndrome
• Body mass index 18.5-35 kg/m2

You may not qualify if:

• Endocrine disorders (cushing syndrome-congenital adrenal hyperplasia)
• Systemic disease
• Use of oral contraceptive,glucocorticoid and antiandrogen
• Use of ovulation induction or dopaminergic agents
• Use of antidiabetes, anti obesity drugs
• history of tubal or ovarian surgery

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Women Health Hospital - Assiut university

Asyut, 71111, Egypt

Location

MeSH Terms

Conditions

Polycystic Ovary Syndrome

Condition Hierarchy (Ancestors)

Ovarian Cysts; Cysts; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Gonadal Disorders; Endocrine System Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of obstetrics and gynecology

Study Record Dates

• First Submitted: May 16, 2017
• First Posted: May 17, 2017
• Study Start: April 1, 2016
• Primary Completion: April 1, 2017
• Study Completion: May 1, 2017
• Last Updated: May 17, 2017

Record last verified: 2017-05

Locations

EG (1)